Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

This policy addresses hematopoietic cell transplantation (autologous or allogeneic hematopoietic stem cell transplantation, including high‑dose chemotherapy with stem‑cell support) as a contemplated treatment for epithelial ovarian cancer — e.g., consolidation after debulking and first‑line chemotherapy (FIGO IIC–IV), restoration of marrow after marrow‑toxic therapy, and for relapsed or refractory disease. However, HCT for epithelial ovarian cancer is considered experimental/investigational and not covered due to insufficient randomized evidence (no demonstrated overall‑survival benefit), is not supported by NCCN, aligns with CMS noncoverage for most solid tumors, and any coverage would be subject to the member’s benefit contract/SPD and applicable Medicare NCD/local determinations.

"Cytoreductive surgery with adjuvant chemotherapy for advanced epithelial ovarian cancer."